Levosimendan improves diastolic and systolic function in failing human myocardium

European Journal of Pharmacology

Volumn 404, Issue 1-2, 2000, Pages 191-199

  Janssen, Paul M L ^a   Datz, Nicolin ^a   Zeitz, Oliver ^a   Hasenfuss, Gerd ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Ca2+ sensitizer; Diastolic dysfunction; Excitation contraction coupling; Heart failure; Hemodynamics; Inotropic agent

Indexed keywords

CALCIUM SENSITIZER; LEVOSIMENDAN;

ADULT; AGED; ARTICLE; DIASTOLE; DRUG EFFECT; DRUG MECHANISM; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART RATE; HUMAN; HUMAN TISSUE; INOTROPISM; MALE; MUSCLE TWITCH; PRIORITY JOURNAL; SYSTOLE;

CARDIOTONIC AGENTS; DIASTOLE; HEART; HUMANS; HYDRAZONES; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PYRIDAZINES; SYSTOLE;

EID: 0034666682     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00609-9     Document Type: Article

References (32)

1. Arai M., Alpert N.R., MacLennan D.H., Barton P., Periasamy M. Alterations in sarcoplasmic reticulum gene expression in human heat failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ. Res. 72:1993;463-469.
2. Böhm M., Gierschik P., Jacobs K.H., Pieske B., Schnabel P., Ungerer M., Erdmann E. Increase in Giα in human hearts with dilated but not ischemic cardiomyopathy. Circulation. 82:1990;189-197.
3. Bristow M.R., Ginsburg R., Minobe W., Cubicciotti R.S., Sageman W.S., Lurie K., Billingham M.E., Harrison D.C., Stinson E.B. Decreased cathecholamine sensitivity and β-adrenergic receptor density in failing human heart. N. Engl. J. Med. 307:1982;205-211.
4. Dies F., Krell M.J., Whitlow P., Liang C., Goldenberg I., Applefeld M.M., Gilbert E.M. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation. 74:1986;II38. (abstract).
5. Feldman A.M., Cates A.E., Veazey W.B., Hershberger R.E., Bristow M.R., Baughman K.L., Baumgartner W.A., Van Drop C. Increase of the 40. 000-mol wt pertussis toxin substrate (G-protein) in the failing human heart J. Clin. Invest. 82:1988;189-197.
6. Grossman W. Diastolic dysfunction and congestive heart failure. Circulation. 81(Suppl. III):1990;III-1-III-7.
7. Gwathmey J.K., Slawsky M.T., Hajjar R.J., Briggs G.M., Morgan J.P. Role of intracellular calcium handling in force-interval relationship of human ventricular myocardium. J. Clin. Invest. 85:1990;1599-1613.
8. Haikala H., Linden I.B. Mechanisms of action of calcium-sensitizing drugs. J. Cardiovasc. Pharmacol. 26(Suppl. 1):1995;S10-S19.
9. Haikala H., Nissinen E., Etemandzadeh E., Levijoki J., Linden I.B. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J. Cardiovasc. Pharmacol. 25:1995;794-801.
10. Haikala H., Kaivola J., Nissinen E., Wall P., Levijoki J., Linden I.B. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J. Mol. Cell. Cardiol. 27:1995;1859-1866.
11. Haikala H., Levojoki J., Linden I.B. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J. Mol. Cell. Cardiol. 27:1995;2155-2165.
12. Hajjar R.J., Gwathmey J.K. Calcium-sensitizing inotropic agents in the treatment of heart failure: a critical review. Cardiovasc. Drugs Ther. 5:1991;961-966.
13. 2+ sensitizers impair cardiac relaxation in failing human myocardium. J. Pharmacol. Exp. Ther. 280:1997;247-254.
14. Hasenfuss G., Mulieri L.A., Allen P.D., Just H., Alpert N.R. Influence of isoproterenol and ouabain on excitation-contraction coupling, cross-bridge function, and energetics in failing human myocardium. Circulation. 94:1996;3155-3160.
15. Hasenfuss G., Pieske B., Castell M., Kretschmann B., Maier L.S., Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 98:1998;2141-2147.
16. Hasenfuss G., Pieske B., Kretschmann B., Holubarsch C., Alpert N.R., Just H. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J. Cardiovasc. Pharmacol. 26(Suppl. I):1995;S45-S51.
17. 2+-ATPase in failing and non-failing myocardium. Circ. Res. 75:1994;434-442.
18. Higashiyama A., Watkins M.W., Chen Z., LeWinter M.M. Effects of EMD 57033 on contraction and relaxation in isolated rabbit hearts. Circulation. 92:1995;3094-3104.
19. Janssen P.M.L., Hunter W.C. Force, not sarcomere length, correlates with prolongation of isosarcometric contraction. Am. J. Physiol. 269:1995;H676-H685.
20. Janssen P.M.L., Lehnart S.E., Prestle J., Hasenfuss G. Preservation of contractile characteristics of human myocardium in multi-day cell culture. J. Mol. Cell. Cardiol. 31:1999;1419-1427.
21. Kleerekoper Q., Putkey J.A. Drug binding to cardiac troponin C. J. Biol. Chem. 274:1999;23932-23939.
22. Lilleberg J., Nieminen M.S., Akkila J., Heikkila L., Kuitunen A., Lehtonen L., Verkakala K., Mattila S., Salmenpera M. Effects of a new calcium sensitizer, levosimendan, on hemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur. Heart J. 19:1998;660-668.
23. Mulieri L.A., Hasenfuss G., Leavitt B., Allen P.D., Alpert N.R. Altered myocardial force-frequency relation in human heart failure. Circulation. 85:1982;1743-1750.
24. Nijhawan N., Nicolosi A.C., Montgomery M.W., Aggarwal A., Pagel P.S., Waltier D.C. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J. Cardiovasc. Pharmacol. 34:1999;219-228.
25. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., DiBianco R., Zeldis S.M., Hendrix G.H., Bommer W.J., Elkayam U., Kukin M.L. Effects of oral milrinone on mortality in severe chronic heart disease. N. Engl. J. Med. 325:1991;1468-1475.
26. Pieske B., Kretschmann B., Meyer M., Holubarsch C., Weirich J., Posival H., Minami K., Just H., Hasenfuss G. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation. 92:1995;1169-1178.
27. 2+-sensitizer, levosimendan, to recombinant human cardiac troponin C. J. Biol. Chem. 269:1994;28584-28590.
28. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1 loaded ventricular cardiomyocytes of the rabbit. J. Mol. Cell. Cardiol. 30:1998;1115-1128.
29. Solaro R.J., Gambassi G., Washaw D.M., Keller M.R., Spurgeon H.A., Beier N., Lakatta E.G. Stereoselective actions of thiadiazones on canine cardiac myocytes and myofilaments. Circ. Res. 73:1993;981-990.
30. Uretsky B.F., Jessup M., Konstam M.A., Dec G.W., Leier C.V., Benotti J., Mulari S., Herrmann H.C., Sandberg J.A. Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared to placebo. Circulation. 82:1990;774-780.
31. 2+ and cross-bridges in skeletal muscle thin filament activation probed with calcium sensitizers. Biophys. J. 76:1999;2166-2176.
32. Zimmermann N., Boknik P., Gams E., Herzig J.W., Neumann J., Scholz H. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure? Eur. J. Cardiothorac. Surg. 14:1998;70-75.